The obesity-drug market has entered a new phase in 2026: GLP-1 weight-loss medicines are moving from weekly injections to daily pills. Two major oral options now competing in the U.S. are Wegovy tablets (semaglutide) from Novo Nordisk and Foundayo (orforglipron) from Eli Lilly.
But how much does the new oral GLP-1 drug cost? The answer depends on the drug, dose, insurance coverage and manufacturer savings programs.
How Much Does the Wegovy Pill Cost?
Wegovy tablets (semaglutide) are Novo Nordisk’s oral version of its well-known obesity treatment.
For eligible U.S. self-pay patients, NovoCare currently lists some Wegovy tablet doses at $149 per month. The promotional price for the 4 mg tablet is available through August 31, 2026, after which the listed self-pay price is scheduled to increase to $199 per month.
The tablet is taken once daily, offering an alternative for people who prefer an oral GLP-1 medication over an injection.
The launch has attracted significant attention, although Novo Nordisk’s August 2026 earnings report showed that Wegovy pill sales came in slightly below analysts’ expectations.
Foundayo (Orforglipron) Cost
The other major new oral GLP-1 drug is Foundayo (orforglipron), developed by Eli Lilly.
Foundayo received U.S. FDA approval in April 2026 and became available shortly afterward. Unlike some oral GLP-1 medicines, it can be taken without food or water restrictions, making its administration relatively simple.
For self-pay patients, Foundayo initially launched at $149 per month, while eligible commercially insured patients could pay as little as $25 per month through Lilly’s savings program.
Lilly’s current pricing information lists a $649 monthly list price for a 30-day supply, although eligible patients may pay substantially less through insurance and savings programs.
Oral GLP-1 Drugs: Wegovy vs Foundayo
| Drug | Active ingredient | Type | U.S. cost* |
|---|---|---|---|
| Wegovy pill | Semaglutide | Daily oral GLP-1 | From $149/month |
| Foundayo | Orforglipron | Daily oral GLP-1 | From $149/month self-pay |
| Foundayo list price | Orforglipron | Daily oral GLP-1 | $649/month |
*Prices and eligibility can change. Insurance coverage and manufacturer programs can substantially reduce the amount a patient actually pays.
Why Are Oral GLP-1 Drugs Important?
The shift to tablets could make obesity treatment more convenient for some patients who dislike injections. It also intensifies competition between Novo Nordisk and Eli Lilly, two of the biggest players in the rapidly expanding obesity-drug market.
However, price should not be the only consideration. GLP-1 medicines are prescription drugs and can have significant side effects and contraindications. Treatment should be selected with a qualified healthcare professional based on medical history, weight-related conditions, medications and treatment goals.
Bottom Line
In 2026, the new oral GLP-1 drugs cost roughly $149 per month at advertised self-pay starting prices, but actual costs vary widely. Wegovy tablets (semaglutide) and Foundayo (orforglipron) are now at the center of the oral obesity-pill race.
For anyone comparing weight-loss treatments, understanding monthly price, effectiveness, eligibility, side effects and long-term affordability is more useful than looking at the headline price alone.
